Citi Upgrades Amarin Corporation (AMRN) to Buy, Anticipates Strong Sales Growth

Citi analyst Joel Beatty upgraded Amarin Corporation (NASDAQ: AMRN) from Neutral to Buy with a price target of $24.00 (from $27.00).

The analyst comments "We still believe Vascepa sales will accelerate strongly over the next couple years. With AMRN trading ~27% lower since November, we see now as an attractive time to buy. Also, we believe AMRN will likely emerge from the ongoing IP litigation with Vascepa exclusivity largely intact "

For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.

Shares of Amarin Corporation closed at $17.62 yesterday.

You May Also Be Interested In

• New Street Research Upgrades Micron Technology (MU) to Buy
• LG Electronics India (LGEL:IN) PT Raised to INR1,815 at ICICI Securities
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker